Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 8/2019

01-08-2019 | Surgery | Peritoneal Surface Malignancy

RAS Mutation Decreases Overall Survival After Optimal Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy of Colorectal Peritoneal Metastasis: A Modification Proposal of the Peritoneal Surface Disease Severity Score

Authors: A. Arjona-Sanchez, PhD, L. Rodriguez-Ortiz, MD, D. Baratti, MD, M. A. Schneider, MD, A. Gutiérrez-Calvo, PhD, A. García-Fadrique, PhD, J. B. Tuynman, PhD, P. A. Cascales-Campos, PhD, V. Concepción Martín, MD, R. Morales, PhD, G. I. Salti, MD, X. Arteaga, PhD, D. Pacheco, PhD, J. Alonso-Gomez, PhD, O. Yalkin, MD, P. Villarejo-Campos, PhD, J. M. Sanchez-Hidalgo, PhD, A. Casado-Adam, PhD, A. Cosano-Alvarez, PhD, S. Rufian-Peña, PhD, J. Briceño, PhD

Published in: Annals of Surgical Oncology | Issue 8/2019

Login to get access

Abstract

Background

Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) are currently the most accepted treatment for peritoneal metastases from colorectal cancer. Restrictive selection criteria are essential to obtain the best survival benefits for this complex procedure. The most widespread score for patient selection, the peritoneal surface disease severity score (PSDSS), does not include current biological factors that are known to influence on prognosis. We investigated the impact of including RAS mutational status in the selection criteria for these patients.

Methods

We studied the risk factors for survival by multivariate analysis using a prospective database of consecutive patients with carcinomatosis from colorectal origin treated by CRS and HIPEC in our unit from 2009 to 2017. The risk factors obtained were validated in a multicentre, international cohort, including a total of 520 patients from 15 different reference units.

Results

A total of 77 patients were selected for local análisis. Only RAS mutational status (HR: 2.024; p = 0.045) and PSDSS stage (HR: 2.90; p = 0.009) were shown to be independent factors for overall survival. Early PSDSS stages I and II associated to RAS mutations impaired their overall survival with no significant differences with PSDSS stage III overall survival (p > 0.05). These results were supported by the international multicentre validation.

Conclusions

By including RAS mutational status, we propose an updated RAS-PSDSS score that outperforms PSDSS alone providing a quick and feasible preoperative assessment of the expected overall survival for patients with carcinomatosis from colorectal origin undergone to CRS + HIPEC.
Literature
1.
Mirnezami R, Mehta AM, Chandrakumaran K, et al. Cytoreductive surgery in combination with hyperthermic intraperitoneal chemotherapy improves survival in patients with colorectal peritoneal metastases compared with systemic chemotherapy alone. Br J Cancer. 2014;111:1500–8.CrossRefPubMedPubMedCentral
2.
Arjona-Sánchez A, et al. Peritoneal metastases of colorectal origin treated by cytoreduction and HIPEC: an overview. World J Gastrointest Oncol. 2014;6:407.CrossRefPubMedPubMedCentral
3.
Franko J, Ibrahim Z, Gusani NJ, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion versus systemic chemotherapy alone for colorectal peritoneal carcinomatosis. Cancer. 2010;116:3756–62.CrossRef
4.
Cavaliere F, De Simone M, Virz S, et al. Prognostic factors and oncologic outcome in 146 patients with colorectal peritoneal carcinomatosis treated with cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy: Italian multicenter study S.I.T.I.L.O. Eur J Surg Oncol. 2011; 37: 148–54.
5.
Kwakman R, Schrama AM, van Olmen JP, et al. Clinicopathological parameters in patient selection for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer metastases: a meta-analysis. Ann Surg. 2016;263(6):1102–11.CrossRefPubMed
6.
Pelz O, Stojadinovic A, Nissan A, Hohenberger W, Esquivel J. Evaluation of a peritoneal surface disease severity score in patients with colon cancer and peritoneal dissemination. J Surg Oncol. 2009;99:9–15.CrossRefPubMed
7.
Esquivel J, Lowy AM, Markman M, et al. The American Society of peritoneal surface malignancies (ASPSM) multi-institution evaluation of the peritoneal surface disease severity score (PSDSS) in 1,013 patients with colorectal cancer with peritoneal carcinomatosis. Ann Surg Oncol. 2014;21:4195.CrossRef
8.
Vauthey JN, Zimmitti G, Kopetz SE, et al. RAS mutations status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases. Ann Surg. 2013;258:619–26.CrossRefPubMed
9.
Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008;359:1757–65.CrossRef
10.
De Roock W, Claes B, Bernasconi D, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy–refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 2010;11:753–62.CrossRefPubMed
11.
Arjona-Sanchez A, Cadenas-Febres A, Cabrera-Bermon J, et al. Assessment of RIFLE and AKIN criteria to define acute renal dysfunction for HIPEC procedures for ovarian and nonovarian peritoneal malignances. Eur J Surg Oncol. 2016;42:869–76.CrossRefPubMed
12.
COMPASS. Simkens GA, van Oudheusden TR, Nieboer D, et al. Development of a prognostic nomogram for patients with peritoneally metastasized colorectal cancer treated with cytoreductive surgery and HIPEC. Ann Surg Oncol. 2016;23:4214–21.
13.
14.
Cashin PH, Graf W, Nygren P, Mahteme H. Patient selection for cytoreductive surgery in colorectal peritoneal carcinomatosis using serum tumor markers: an observational cohort study. Ann Surg. 2012;256:1078–83.CrossRefPubMed
15.
Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26:1626–34.CrossRef
16.
Douillard J-Y, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, et al. Panitumumab–FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med. 2013;369:1023–34.CrossRefPubMed
17.
Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009;360:1408–17.CrossRef
18.
Lievre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 2006;66:3992–5.CrossRefPubMed
19.
Brudvik KW, Kopetz SE, Li L, et al. Meta-analysis of KRAS mutations and survival after resection of colorectal liver metástasis. Br J Surg. 2015;102:1175–83.CrossRefPubMed
20.
21.
Prada-Villaverde A, Esquivel J, Lowy AM, et al. The American Society of peritoneal surface malignancies evaluation of HIPEC with mitomycin C versus oxaliplatin in 539 patients with colon cancer undergoing a complete cytoreductive surgery. J Surg Oncol. 2014. https://​doi.​org/​10.​1002/​jso.​23728.
22.
Hompes D, D’Hoore A, Wolthuis A, Fieuws S, Mirck B, Bruin S, et al. The use of Oxaliplatin or Mitomycin C in HIPEC treatment for peritoneal carcinomatosis from colorectal cancer: a comparative study. J Surg Oncol. 2014;109:527–32.CrossRefPubMed
23.
Venderbosch S, Nagtegaal ID, Maughan TS, et al. Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies. Clin Cancer Res. 2014;20:5322–30.CrossRefPubMedPubMedCentral
Metadata
Title
RAS Mutation Decreases Overall Survival After Optimal Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy of Colorectal Peritoneal Metastasis: A Modification Proposal of the Peritoneal Surface Disease Severity Score
Authors
A. Arjona-Sanchez, PhD
L. Rodriguez-Ortiz, MD
D. Baratti, MD
M. A. Schneider, MD
A. Gutiérrez-Calvo, PhD
A. García-Fadrique, PhD
J. B. Tuynman, PhD
P. A. Cascales-Campos, PhD
V. Concepción Martín, MD
R. Morales, PhD
G. I. Salti, MD
X. Arteaga, PhD
D. Pacheco, PhD
J. Alonso-Gomez, PhD
O. Yalkin, MD
P. Villarejo-Campos, PhD
J. M. Sanchez-Hidalgo, PhD
A. Casado-Adam, PhD
A. Cosano-Alvarez, PhD
S. Rufian-Peña, PhD
J. Briceño, PhD
Publication date
01-08-2019
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 8/2019
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-019-07378-9

Other articles of this Issue 8/2019

Annals of Surgical Oncology 8/2019 Go to the issue

Hepatobiliary Tumors

Prognostic Value and Prediction of Extratumoral Microvascular Invasion for Hepatocellular Carcinoma

ASO Author Reflections

ASO Author Reflections: Tending Towards a Personalized Medicine for Colorectal Carcinomatosis by Adding the RAS Mutation Status in the Workup for CRS and HIPEC

Hepatobiliary Tumors

Recurrence Patterns and Timing Courses Following Curative-Intent Resection for Intrahepatic Cholangiocarcinoma

Head and Neck Oncology

Elective Paratracheal Lymph Node Dissection in Salvage Laryngectomy

Melanoma

Let’s Not Forget About Regional Therapy for the Treatment of Locally Advanced Extremity Melanoma

Thoracic Oncology

Predicting the Risk of Weight Loss After Esophageal Cancer Surgery